NPJ precision oncology · 2025
A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sobral-Leite Marcelo, Castillo Simon P, Vonk Shiva, Messal Hendrik A, Melillo Xenia, Lam Noomie, de Bruijn Brandi, Hagos Yeman B, van den Bos Myrna, Sanders Joyce, Almekinders Mathilde, Visser Lindy L, Groen Emma J, Kristel Petra, Ercan Caner, Azarang Leyla, van Rheenen Jacco, Hwang E Shelley, Yuan Yinyin, Grand Challenge PRECISION Consortium, Menezes Renee, Lips Esther H, Wesseling Jelle
Аннотация
Ductal carcinoma in situ (DCIS) may progress to ipsilateral invasive breast cancer (iIBC), but often never will. Because DCIS is treated as early breast cancer, many women with harmless DCIS face overtreatment. To identify features associated with progression, we developed an artificial intelligence-based DCIS morphometric analysis pipeline (AIDmap) on hematoxylin-eosin-stained (H&E) tissue sections. We analyzed 689 digitized H&Es of pure primary DCIS of which 226 were diagnosed with subsequent iIBC and 463 were not. The distribution of 15 duct morphological measurements was summarized in 55 morphometric variables. A ridge regression classifier with cross validation predicted 5-years-free of iIBC with an area-under the curve of 0.67 (95% CI 0.57-0.77). A combined clinical-morphometric signature, characterized by small-sized ducts, a low number of cells and a low DCIS/stroma ratio, was associated with outcome (HR = 0.56; 95% CI 0.28-0.78). AIDmap has potential to identify harmless DCIS that may not need treatment.